Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurosense Therapeutics Ltd. ( (NRSN) ) has issued an announcement.
On February 18, 2026, NeuroSense Therapeutics reported new long-term survival data from its completed PARADIGM Phase 2b trial of PrimeC in ALS, showing a clinically meaningful and statistically significant survival advantage for patients continuously treated with the drug. Patients on uninterrupted PrimeC therapy had an estimated median survival of 36.3 months versus 21.4 months for those who started on placebo before crossing over, a gain of more than 14 months and roughly 70% longer median survival, with persistent separation of survival curves over time.
The updated analysis, supported by a significant log-rank test and a Cox model indicating a 65% reduction in risk of death versus placebo after adjusting for baseline factors, reinforces earlier findings that PrimeC slows disease progression with favorable safety in the 68-patient randomized, double-blind, placebo-controlled study. NeuroSense said the survival findings materially strengthen the clinical and regulatory case for PrimeC as it engages health authorities on advancing the program into pivotal late-stage development, potentially enhancing the company’s positioning in the ALS treatment landscape and its value proposition for patients and investors.
The most recent analyst rating on (NRSN) stock is a Hold with a $0.90 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a clinical-stage, late-stage-focused biotechnology company developing disease-modifying combination therapies for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease. Its lead candidate, PrimeC, is an extended-release oral formulation combining ciprofloxacin and celecoxib to target multiple ALS and Alzheimer’s-related pathways, including neuroinflammation, iron accumulation and impaired RNA regulation.
Average Trading Volume: 338,762
Technical Sentiment Signal: Sell
Current Market Cap: $30.89M
For an in-depth examination of NRSN stock, go to TipRanks’ Overview page.